medigraphic.com
ISSN 1561-3046 (Electronic)

2020, Number 1

<< Back Next >>

Rev Cub Med Mil 2020; 49 (1)

Sildenafil monotherapy in patients with severe pulmonary hypertension

Vega CR

Language: Spanish
References: 36
Page: 15-29
PDF size: 427.15 Kb.


ABSTRACT

Introduction: Treatment with phosphodiesterase 5 inhibitors in patients with acquired and congenital heart disease, with pulmonary hypertension, can improve the quality and prognosis of life, both in surgical and non-surgical heart disease, with severe pulmonary hypertension.
Objectives: To analyze the results of sildenafil monotherapy in surgical and non-surgical patients, with congenital and acquired heart disease and severe pulmonary hypertension.
Method: Descriptive study in 60 patients who received sildenafil for severe pulmonary arterial hypertension, secondary to congenital left acquired heart disease. It was observed: dose, duration of treatment, tolerance, clinical and echocardiographic evolution, functional class and surgical treatment according to cardiac catheterization results.
Results: In the period between December 2017 and December 2018, 20 patients with left heart valvular disorders, 8 congenital and 3 primary cardiac tumors, with sildenafil daily administration doses of 100 to 150 milligrams, were operated with severe pulmonary arterial hypertension. There were 29 other patients with heart disease, which although they were not surgical, improved their quality and prognosis of life.
Conclusions: The prescription of sildenafil was useful to improve the quality and prognosis of life, both in surgical and non-surgical patients with heart disease and severe pulmonary hypertension.


REFERENCES

  1. Murad F. Nitric oxide and cyclic GMP in cell signaling and drug development. N Engl J Med. 2006 Nov [acceso: 10/01/2019];355(19):2003-11. Disponible en: https://www.nejm.org/doi/full/10.1056/NEJMsa063904

  2. Miguel E, Beltrán Gámez J, Sandoval Z y Pulido T. Inhibidores de fosfodiesterasa-5 para el tratamiento de la hipertensión arterial pulmonar. Arch. Cardiol. Méx. 2015 [acceso: 15/05/2019]; 85(3):215-24. Disponible en: https://www.scielo.org.mx/pdf /acm/ v85n3/v85n3a7.pdf

  3. Monserrat L, Penas Lado M, Castro Beiras A. Esperanzas y experiencias en el tratamiento de la hipertensión arterial pulmonar severa. Rev. Esp. Cardiología. Marzo 2003; [acceso: 12/01/2019]; 56(3): 228-29. Disponible en: https://www.revespcardiol.org/es-pdf-13043947

  4. Calderón Colmenero J, Sandoval Zárate J, Beltrán Gámez M. Hipertensión pulmonar asociada a cardiopatías congénitas y síndrome de Eisenmenger. Archivos de Cardiología de México . 2015[acceso: 01/02/2019]; 85(1) :32-49. Disponible en: https://www.elsevier.es/es-revista-archivos-cardiologia-mexico-293-pdf-S1405994014001918

  5. García HRA, Castro AAM, Ramos EC, Rivero SL. Eisenmenger syndrome. A case presentation. Revista de Ciencias Médicas de la Habana 2014[acceso: 01/02/2019];20(3): 435-440. Disponible en: https://www.medigraphic.com/pdfs/revciemedhab/cmh-2014/cmh143n.pdf

  6. León Aguilar DE, Arteaga Mancera MP, Iglesias Leboreiro J, Bernárdez Zapata I. Sildenafilo en el tratamiento de la hipertensión pulmonar en los recién nacidos. Rev. Méx. Cardiología. 2014[acceso: 08/02/2019];81(2):61-63. Disponible en: https://www.medigraphic.com/pdfs/pediat/sp-2014/sp142d.pdf

  7. Iversen K, Jensen SA, Jensen VT, Vejlstrup GN, Sondergaard L. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J. 2010[acceso: 08/02/2019];31(9):1124-31. Disponible en: https://pdfs.semanticscholar.org/ fc8f/037fc2ba808058a30cfe5ba8a45f2 baf72 b9.pdf?_ga=2.155685949.745037846.1567706697-1784513207.1545434283

  8. Schermuly RT, Stasch JP , Pullamsetti SS , Middendorff R , Müller D , Schlüter KD , et al. Expresión y función de guanilato ciclasa soluble en hipertensión arterial pulmonar. Eur Respir J. 2008 Oct [acceso: 09/02/2019];32(4):881-91. Disponible en: https://erj.ersjournals.com/content/32/4/881.long

  9. Fermandois CM, López BR, León SP, Lema FG. Hipertensión pulmonar y el paciente quirúrgico: Estrategias de manejo actual. Rev. Med. Chile. abr. 2010[acceso: 18/02/2019]; 138 (4):496503. Disponible en: https://scielo.conicyt.cl/scielo.php? script= sciarttext&pid=S0034-98872010000400016

  10. Ning ZZ, Jiang X, Zhang R, Li LX, Xiang Wu B, Zhao HQ, et al. Oral sildenafilo treatment for Eisenmenger syndrome: a prospective, openlabel, multicentre study. Heart. 2011 [acceso: 18/02/2019]; 97(22): 1876-81. Disponible en: https://heart.bmj.com/content/97/22/1876

  11. Takimoto E, Belardi D, Tocchetti CG, Vahebi S, Cormaci G, Ketner EA, et al. Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation. 2005[acceso: 20/02/2019];112(2):642-9. Disponible en: https://www.ahajournals.org/doi/pdf/10.1161/01.RES.0000152262.22968.72

  12. Galiè N, Hoepe M, Humbert M, Torbicki A, Vachiery LJ, Barberá AJ, et al. Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar. Rev Esp Cardiol. 2009[acceso: 20/02/2019]; 62(12): 1464.e1-e58. Disponible en: https://www.revespcardiol.org/es-pdf-13145647

  13. Takimoto E, Champion HC, Berardi D, Susan VC, Elizabeth, et al. Glutamil Monofosfato ciclico (cGMP) catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res. 2005[acceso: 24/02/2019]; 96:100-9. Disponible en: https://www.ahajournals.org/doi/full/10.1161/01.RES.0000152262.22968.72

  14. Nagayama T, Hsu S, Zhang M, Koitabashi N, Bedja D, Gabrielson KL, et al. Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J Am Coll Cardiol. 2009[acceso: 28/02/2019];53(2):207-15. Disponible en: https://www.sciencedirect.com/science/article/pii/ S0735109708034086? via%3Dihub

  15. Reffelman T, Kloner RA. Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation. 2003[acceso: 04/03/2019]3; 108(2):239-44. Available: https://www.ahajournals.org/doi/full/10.1161/01.CIR.0000081166.87607.E2

  16. Ghofrani HA, Voswinckel R, Reichenberger F. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension. A randomized prospective study. J Am Coll Cardiol. 2004[acceso: 10/03/2019]; 44(7):1488-96. Disponible en: https://www.sciencedirect.com/science/article/pii/S0735109704013622?via%3Dihub

  17. Brindis R, Kloner R. Sildenafil in Patients with Cardiovascular Disease. American Journal of Cardiology. 2019[acceso: 21/07/2019];92(9A):26-36.Disponible en: https://www.ahajournals.org/doi/full/10.1161/01.cir.0000146906.42375.d3

  18. Singh TP, Rohit M, Grover A, Malhotra S, Vijayvergiya RA. randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J. 2006[acceso: 14/03/2019];151(4):851-55. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0002870305008513?via%3Dihub

  19. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. N Engl J Med. 2005[acceso: 14/03/2019]5; 353(20):2148-57. Disponible en: https://www.nejm.org/doi/full/10.1056/NEJMoa050010

  20. Rubin LJ, Badesch DB, Fleming TR, Galiè N, Simonneau G, Ghofrani HA, et al. Long-Term treatment with sildenafil citrate in pulmonary arterial hypertension: The SUPER-2 study. Chest. 2011[acceso: 16/03/2019]; 140(5):1274-83. Disponible en: https://journal.chestnet.org/article/S0012-3692(11)60595-3/fulltext

  21. Simonneau G, Rubin L, Galie N. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension. Ann Intern Med. 2008[acceso: 17/03/2019]; 149(8):521-30. Disponible en: https://annals.org/aim/article-abstract/743198/addition-sildenafil-long-term-intravenous-epoprostenol-therapy-patients-pulmonary-arterial?volume=149&issue=8&page=521

  22. Nazzareno G, Marc H, Jean LV, Gibbs S, Lang I, Torbicki A, et al. Guía ESC/ERS 2015 sobre diagnóstico y tratamiento de la hipertensión pulmonar y Comité de Guías de la SEC. Rev. Esp Cardiol. 2016 [acceso: 22/03/2019]; 69(2):102-8. Disponible en: https://www.revespcardiol.org/es-comentarios-guia-esc-ers-2015-sobre-articulo-S0300893216000026?redirect=true

  23. Zagolin M, Llancaqueo M. Hipertensión pulmonar: importancia de un diagnóstico precoz y tratamiento específico. Rev. Med. Clin. Condes. 2015[acceso: 24/03/2019]; 26(3): 344-356. Disponible en: https://www.elsevier.es/es-revista-revista-medica-clinica-las-condes-202-pdf-S0716864015000693

  24. Bigna JJ, Sime PS, Koulla Shiro S. HIV related pulmonary arterial hypertension: epidemiology in Africa, Physiopathology, and role of antiretroviral treatment. AIDS Res Ther. (2015) [acceso: 28/03/2019];12(1):36. Disponible en: https://aidsrestherapy.biomedcentral.com/articles/10.1186/s12981-015-0078-3

  25. Beltrán Gámez ME, Sandoval Zárate J, Pulido T. Inhibidores de fosfodiesterasa-5 para el tratamiento de la hipertensión arterial pulmonar. Arch Cardiol. 2015[acceso: 02/04/2019];85(3):215-24. Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S1405-99402015000300007

  26. Pugh ME, Sivarajan L, Wang L, Robbins IM, Newman JH, Hemnes AR. Causes of pulmonary hypertension in the elderly. Chest 2014[acceso: 15/05/2019];146(1):159-166. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0012369215487604

  27. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I , Torbicki A , et al. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Pediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Euro Heart J. 2016 Jan 1 [acceso: 16/05/2019]; 37(1):67-119. Available in: http://www.Precisdanes thesiecardiaque.ch/Pdf/AnnEAnesth/HTA%20Pulm%20ESC.pdf

  28. Trujillo P. Cardiopatías congénitas del adulto. Rev. Urug. Cardiol. Montevideo. 2014[acceso: 17/05/2019];29(3):623-31 Disponible en: http://www.scielo.edu.uy/scielo.php?script=sci_arttext&pid=S1688-04202014000300023

  29. Navas P, Tenorio J, Quezada CA, Barrios E, Gordo G, Arias P, et al. Análisis molecular de BMPR2, TBX4 y KCNK3 y correlaciones genotipo-fenotipo en pacientes españoles y familias con hipertensión arterial pulmonar idiopática y hereditaria. Rev. Esp Cardiol (Engl Ed). 2016 Nov [acceso: 20/05/2019]; 69(11):1011-19. Disponible en: https://www.revespcardiol.org/en-linkresolver-molecular-analysis-bmpr2-tbx4-kcnk3-S1885585716301311

  30. Lewis GD, Shah R, Shahzad K, Camuso J, Pappagianopoulos PP, Hung J, et al. Sildenafil improves excercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary arterial hypertension. Circulation 2007[acceso: 24/05/2019]; 116(14): 1555-62. Disponible en: https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.107.716373?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr dat=crpub%3dpubmed

  31. Zhang YY, Xu F, Chu M, Bi L. Hipertensión arterial pulmonar en pacientes ancianos críticamente enfermos. Pak J Med Sci . Enero-febrero 2017[Acceso: 25/05/2019]; 33 (1): 27-32.Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368323/pdf/PJMS-33-27.pdf

  32. Carrasco Hernández L, Jara Palomares L, Abad Arranz M. Respuesta paradójica a prostanoides en paciente con hipertensión pulmonar severa. Revista Española de Neumología. Julio-Septiembre 2015[acceso: 26/08/2019]; 18(3):121-23. Disponible en: https://www.revistadepatologiarespiratoria.org/revistadepatologiarespiratoria_de-talle_articulo.php?aid=718

  33. Sitbon O, Channick R, Chin KM, Frey A, Gaine S , Galiè N, et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2015 Dec 24[acceso: 30/03/2019]; 373(26):2522-33. Disponible en: https://www.nejm.org/doi/10.1056/NEJMoa1503184?urlver=Z39.88-2003&rfrid=ori:rid:crossref.org&rfrdat=crpub%3dwww.ncbi. nlm.nih.gov

  34. Ghofrani HA, Simonneau G, D'Armini AM, Fedullo P, Howard DPhil LS, Jais X, et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicenter, phase 2, randomized, double-blind, placebo-controlled study. Lancet Respir Med. 2017 Oct [acceso: 15/05/2019]; 5(10):785-94. Disponible en: https://www.thelancet.com/journals/lanres/article/PIIS22132600(17)30305-3/fulltext

  35. Humbert M, Galiè N, McLaughlin VV , Rubin LJ, Simonneau G. Una visión privilegiada del Simposio mundial sobre la hipertensión pulmonar. Lancet Respir Med . junio 2019[acceso: 27/08/2019];7(6):484-85. Disponible en: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(19)30111-0/fulltext

  36. Baliga RS, MacAllister RJ, Hobbs AJ. Nuevas perspectivas para el tratamiento de la hipertensión pulmonar. Br J Pharmacol . 2011 mayo [acceso: 30/08/2019];163(1): 125-40. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085874/pdf/bph0163-0125.pdf




2020     |     www.medigraphic.com